This web only provides the extract of this article. If you want to read the figures and tables, please reference the PDF full text on Blackwell Synergy. Thank you.
- Review -
Recent advances in andrology-related stem cell research
Ching-Shwun Lin1, Zhong-Cheng
Xin2, Chun-Hua Deng3, Hongxiu
Ning1, Guiting Lin1, Tom F. Lue1
1Knuppe Molecular Urology Laboratory, Department of Urology, School of Medicine, University of California, San Francisco, CA 94143, USA
2Andrology Center, Peking University First Hospital, Beijing 100009, China
3Urology Department, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, China
Abstract
Stem cells hold great promise for regenerative medicine because of their ability to self-renew and to differentiate
into various cell types. Although embryonic stem cells (BSC) have greater differentiation potential than adult stem
cells, the former is lagging in reaching clinical applications because of ethical concerns and governmental restrictions.
Bone marrow stem cells (BMSC) are the best-studied adult stem cells (ASC) and have the potential to treat a wide
variety of diseases, including erectile dysfunction (ED) and male infertility. More recently discovered adipose
tissue-derived stem cells (ADSC) are virtually identical to bone marrow stem cells in differentiation and therapeutic potential,
but are easier and safer to obtain, can be harvested in larger quantities, and have the associated benefit of reducing
obesity. Therefore, ADSC appear to be a better choice for future clinical applications. We have previously shown that
ESC could restore the erectile function of neurogenic ED in rats, and we now have evidence that ADSC could do so
as well. We are also investigating whether ADSC can differentiate into Leydig, Sertoli and male germ cells. The
eventual goal is to use ADSC to treat male infertility and testosterone deficiency.
(Asian J Androl 2008 Mar; 10: 171_175)
Keywords: stem cells; bone marrow stem cells; adipose tissue-derived stem cells; erectile dysfunction; male infertility
Correspondence to: Dr Ching-Shwun Lin, Knuppe Molecular Urology Laboratory, Department of Urology, School of Medicine,
University of California, San Francisco, CA 94143, USA.
Tel: +1-415-476-3800 Fax: +1-415-476-3803
E-mail: clin@urology.ucsf.edu
Received 2007-12-12 Accepted 2008-01-11
DOI: 10.1111/j.1745-7262.2008.00389.x
1 Introduction
Stem cells are endowed with the capacity to self-renew and to differentiate into various cell types, depending on
the stimuli (signals) that they received. For ease of discussion, stem cells shall be classified into embryonic stem cells
(ESC) and adult stem cells (ASC). Whereas ESC are derived from the inner cell mass of a blastocyst, ASC usually
originate from various tissues of a developed individual (adult). Because ASC can also be isolated from a developing
individual (fetus, infant or child), they are alternatively called somatic stem cells.
The differentiation potential of stem cells is hierarchized into totipotent, pluripotent and multipotent. A fertilized
egg is totipotent and can differentiate into any cell type. An ESC is pluripotent and can differentiate into any cell type,
except a fertilized egg. An ASC is multipotent and can differentiate into most cell types of its tissue origin. However,
numerous studies have shown that ASC can differentiate into cell types beyond their tissue origin
(e.g. bone marrow stem cells [BMSC] differentiating into cardiomyocytes); therefore, ASC appear to
possess a certain degree of pluripotency [1_3]. In any case, although ESC is undoubtedly superior to ASC in differentiation
potential, its research has been hampered by ethical concerns and governmental restrictions. ASC research, in constrast, is moving at a
faster pace and has reached clinical trials ahead of ESC
research.
Various types of ASC have been discovered in various
tissues, the largest class being the mesenchymal stem
cells (MSC), which reside in virtually all post-natal
organs and tissues [4]. Among various types of MSC,
BMSC and hematopoietic stem cells (HSC) were discovered the earliest and have been investigated most
thoroughly. In a normal individual, HSC eventually
differentiate into various hematopoietic cells, such as RBC,
WBC and platelets. BMSC, in contrast, are not as clearly
understood in terms of what cell types they are destined
to become. Available evidence points to their possible
role as replacement cells for the routine maintenance of
normal tissues, such as in the kidney [5], and for the
repair of damaged tissues, such as in an infracted heart [6].
Hundreds of reports have collectively shown that
BMSC can differentiate into various cell types including
adipocytes, endothelial cells, epithelial cells, glial cells,
hepatocytes, neurons, cardiac muscle cells, skeletal muscle
cells and smooth muscle cells [1_3]. Furthermore, many
of these reports have used animal models to demonstrate
the feasibility of using BMSC for treatment of
degenerative and inflammatory diseases.
2 Using stem cells to treat andrological diseases
Compared with other fields, andrology has been
relatively late to embrace stem cells as potential therapeutic
agents, with researches being concentrated in two areas:
erectile dysfunction (ED) and male infertility. In 2003,
Deng et al. [7] showed that BMSC transduced with
eNOS were able to improve the erectile function of aged
rats. In 2004, our research team at the University of
California San Francisco (UCSF) showed that ESC transfected with brain-derived neurotrophic factor
(BDNF) could restore the erectile function of rats whose
cavernous nerves were experimentally damaged [8]. In
2007, three other ED-related papers were published.
Bivalacqua et al. [9] showed that BMSC alone or
transduced with eNOS were able to reverse age-associated
ED. Song et al. [10] showed that magnetic resonance
could be used to non-invasively evaluate human BMSC
in corpus cavernosa of rats and rabbits. Finally, Song
et al. [11] showed that immortalized human BMSC (by
v-myc transfection) transplanted into rat corpus
cavernosum could differentiate into endothelial and smooth
muscle cells.
In regard to male infertility, a 2003 paper by Toyooka
et al. [12] showed that ESC could form male germ cells
in vitro. Specifically, they showed that the
differentiation of ESC into male germ cells depended on embryoid
body formation and was greatly enhanced by the
inductive effects of bone morphogenic protein 4-producing
cells. They further showed that the induced germ cells
could participate in spermatogenesis when transplanted
into reconstituted testicular tubules, demonstrating that
ESC can produce functional germ cells in
vitro. In 2004, another paper by Geijsen et
al. [13] showed that ESC-derived embryoid bodies supported maturation of
primordial germ cells into haploid male gametes, which,
when injected into oocytes, restored the somatic diploid
chromosome complement and developed into blastocysts.
Also in 2004, Nayernia et al. [14] reported the
in vitro generation of a germ cell line (SSC1) from the
pluripotent teratocarcinoma cells and showed that the SSC1 cell
line formed mature seminiferous tubule structures and
supported spermatogenesis after transplantation into
recipient testes. In 2006, West et al. [15] published a
detailed protocol for the in vitro generation of germ cells
from murine ESC. Finally, and most significantly,
Nayernia et al. [16] demonstrated for the first time that
ESC-derived germ cells were able to generate offspring
mice.
Another landmark was reached in 2006 when Nayernia
et al. [17] for the first time showed that
murine BMSC could differentiate into male germ cells. The
human version of this line of research was published the
following year by Drusenheimer et al. [18]. Finally, Lue
et al. [19] showed that BMSC transplanted into the testis
of a busulfan-treated infertility mouse model appeared to
differentiate into germ cells, Sertoli cells and Leydig cells.
This finding raises the possibility of using BMSC to treat
male infertility and testosterone deficiency.
3 The emergence of adipose tissue-derived stem
cells
In a 1999 paper, Stashower et al. [20] showed that
the stromal fraction of adipose tissue contained a large
population (> 75%) of cells that expressed the CD34
antigen, a well-known HSC marker that is also expressed
in BMSC. Although acknowledging that CD34 is expressed in endothelial cells that are part of the stromal
fraction, the authors nevertheless proclaimed the
existence of progenitor cells in the adipose tissue. In a 2000
paper, Halvorsen et al. [21] reported that, depending on
the culture condition, adipose tissue-derived stromal cells
could be induced to express adipocyte-specific or
osteoblast-specific proteins. In 2001, six additional papers
further reported the multipotent nature of cultured
adipose tissue-derived stromal cells. Five of these papers
continued to demonstrate these cells' adipogenic and
osteogenic potential [22_26], while the sixth paper showed
for the first time that these cells could also differentiate
into chondrocytes and myocytes [27]. As of today, near
the end of 2007, there are more than 220 ADSC-related
articles and the list of ADSC-differentiated cell types now
includes endothelial, epithelial, muscle (cardiac, skeletal,
and smooth), Schwann cells, hepatocytes and neurons.
As a new comer in the stem cell circle, ADSC is
naturally subjected to comparison with BMSC, the
prototype of ASC that also resides in an adipose-rich
environment. Although there are the expected
inconsistencies and variations among different studies, the
general consensus is that ADSC and BMSC are virtually
identical in cell surface marker profile, gene expression
profile and differentiation potential [28]. This
consensus has been reaffirmed in a recent preclinical study in
which ADSC and BMSC were found equally effective in
treating a porcine model of cardiac infarction [29].
However, clonogenic studies have established that the
number of BMSC in bone marrow is approximately 1 in
25 000 to 1 in 100 000, whereas the average frequency
of ADSC in processed lipoaspirate is approximately 2%
of nucleated cells [28]. Therefore, the yield of ADSC
from 1 g of fat is approximately 5 000 cells, whereas the
yield of BMSC is 100_1 000 cells per milliliter of morrow.
Furthermore, although bone marrow can only be obtained
in limited quantity, the adipose tissue is usually
obtainable in abundance, especially in our increasingly obese
society. The safety of the tissue isolation procedure is
another advantage of ADSC over BMSC, as it has been
shown that between 1994 and 2000 there were zero deaths
in 66 570 liposuction procedures and a serious adverse
event rate of only 0.068% [30]. Therefore, although
ADSC and BMSC are virtually identical in their
usefulness as regenerative cell sources, the difference in their
clinical application potential is quite obvious.
4 Clinical application of adipose tissue-derived stem
cells
The therapeutic potential of ADSC has been tested in
several medical disciplines, particularly orthopedics,
cardiology and neurology. Although most of these studies
took place in pre-clinical settings (i.e. using animal
models), a few clinical trials involving human patients
have in fact been conducted. In 2004, Lendeckel
et al. [31] reported the successful application of ADSC in
repairing the cranial defects of a 7-year-old girl who
suffered severe head injuries due to an accidental fall. In
2006 and 2007, two separate papers reported the
successful application of ADSC for cosmetic surgeries,
primarily breast augmentation, on more than 70 patients
[32, 33]. Three other papers have reported the use of
ADSC in circumventing graft-versus-host reactions in
human patients [34_36].
5 Potential andrological application of adipose
tissue-derived stem cells
To our knowledge, our research team at UCSF (with
our collaborators at Peking University and Sun Yat-Sen
University) is the only group conducting research on
ADSC to treat andrological diseases, specifically, ED and
infertility. Our research is both basic science and clinical.
On the basic side, we have performed various
experiments to characterize ADSC isolated from mice, rats,
pigs and humans, resulting in the publication of 2 papers
and the submission of 2 manuscripts. In the first
published paper we showed that ADSC could be induced by
isobutylmethylxanthine (IBMX) to differentiate into
neuron-like cells [37]. In the second paper we showed that
the IBMX-induced neuronal differentiation was mediated
by the IGF-I signaling pathway [38]. The significance
of these two studies is that ADSC has the potential to
treat degenerative neurological diseases, including
neurogenic ED, which frequently occurs to patients who
have undergone pelvic floor surgeries or radiation.
We have recently submitted for publication a study
titled "Characterization of stem and progenitor cells in
adipose tissue". This study was motivated by the fact
that, despite having been investigated in more than 220
studies, ADSC remain unidentified in adipose tissue. In
this study we used immunohistochemistry,
immunofluorescence, flow cytometry and western blot analysis to
look for cells expressing vascular and stem cell markers.
The results showed that ADSC are located in or near
blood vessels, especially capillaries. In regard to our
other studies we have obtained evidence of ADSC
differentiating into endothelial, skeletal and smooth muscle
cells. The significance of these studies is that ADSC
undoubtedly have the potential to treat urological and
andrological diseases. In the meanwhile, our medical
researchers have applied ADSC to treat neurogenic ED
in rats and obtained promising results. More recently,
we have been investigating whether ADSC can
differentiate into sperm, Leydig and Sertoli cells.
6 Concluding remarks
Because of their regenerative potential, stem cells are
ideal therapeutic agents for degenerative diseases such
as ED and defective conditions such as male infertility.
In animal studies both ESC and BMSC have shown
promise for treating these two andrological diseases. However,
the challenges facing the use of ESC as a therapeutic
regime are ethical concerns and the expected legal battles
that could postpone its clinical application indefinitely.
Although recent advances have shown that ESC could
be generated through "reprogramming" of somatic cells
[39_41], the clinical application of this type of ESC is
still questionable because of the need to use viral vectors
and the complicated procedure. However, the use of
BMSC for regenerative medicine appears to be more
acceptable to the public and the procedure much less
complicated. Therefore, it can reasonably be expected
that BMSC will reach the bedside ahead of ESC. Nevertheless, given the evidence that BMSC and ADSC
are virtually identical in therapeutic potential, who would
choose the former and not the latter for treating his ED
or infertility?
Although the number of patients who have been treated with ADSC is still too small to make ADSC the
obvious choice among the various types of stem cells,
one additional factor to be considered is that ADSC has
been used commercially to treat more than 2 500 horses
with an approximate success rate of 75% (www.vet-stem.com). Therefore, the evidence for ADSC as a
regenerative medicine is solid, and our own research at
UCSF clearly shows that ADSC is a promising
therapeutic entity for treating andrological diseases.
References
1 Kolf CM, Cho E, Tuan RS. Mesenchymal stromal cells.
Biology of adult mesenchymal stem cells: regulation of niche,
self-renewal and differentiation. Arthritis Res Ther 2007; 9: 204.
2 Phinney DG, Prockop DJ. Concise review: mesenchymal
stem/multipotent stromal cells: the state of transdifferentiation and
modes of tissue repaircurrent views. Stem Cells 2007; 25:
2896_902.
3 Satija NK, Gurudutta GU, Sharma S, Afrin F, Gupta P, Verma
YK, et al. Mesenchymal stem cells: molecular targets for
tissue engineering. Stem Cells Dev 2007; 16: 7_23.
4 da Silva Meirelles L, Chagastelles PC, Nardi NB.
Mesenchymal stem cells reside in virtually all post-natal organs and
tissues. J Cell Sci 2006; 119: 2204_13.
5 Poulsom R, Alison MR, Cook T, Jeffery R, Ryan E, Forbes
SJ, et al. Bone marrow stem cells contribute to healing of the
kidney. J Am Soc Nephrol 2003; 14 (Suppl 1): S48_54.
6 Chiu RC. Bone-marrow stem cells as a source for cell therapy.
Heart Fail Rev 2003; 8: 247_51.
7 Deng W, Bivalacqua TJ, Chattergoon NN, Hyman AL, Jeter
JR Jr, Kadowitz PJ. Adenoviral gene transfer of eNOS:
high-level expression in ex vivo expanded marrow stromal cells. Am
J Physiol Cell Physiol 2003; 285: C1322_9.
8 Bochinski D, Lin GT, Nunes L, Carrion R, Rahman N, Lin CS,
et al. The effect of neural embryonic stem cell therapy in a rat
model of cavernosal nerve injury. BJU Int 2004; 94: 904_9.
9 Bivalacqua TJ, Deng W, Kendirci M, Usta MF, Robinson C,
Taylor BK, et al. Mesenchymal stem cells alone or
ex vivo gene modified with endothelial nitric oxide synthase reverse
age-associated erectile dysfunction. Am J Physiol Heart Circ
Physiol 2007; 292: H1278_90.
10 Song YS, Lee HJ, Park IH, Kim WK, Ku JH, Kim SU.
Potential differentiation of human mesenchymal stem cell
transplanted in rat corpus cavernosum toward endothelial or smooth
muscle cells. Int J Impot Res 2007; 19: 378_85.
11 Song YS, Ku JH, Song ES, Kim JH, Jeon JS, Lee KH,
et al. Magnetic resonance evaluation of human mesenchymal stem
cells in corpus cavernosa of rats and rabbits. Asian J Androl
2007; 9: 361_7.
12 Toyooka Y, Tsunekawa N, Akasu R, Noce T. Embryonic stem
cells can form germ cells in vitro. Proc Natl Acad Sci U S A
2003; 100: 11457_62.
13 Geijsen N, Horoschak M, Kim K, Gribnau J, Eggan K, Daley
GQ. Derivation of embryonic germ cells and male gametes
from embryonic stem cells. Nature 2004; 427: 148_54.
14 Nayernia K, Li M, Jaroszynski L, Khusainov R, Wulf G,
Schwandt I, et al. Stem cell based therapeutical approach of
male infertility by teratocarcinoma derived germ cells. Hum
Mol Genet 2004; 13: 1451_60.
15 West JA, Park IH, Daley GQ, Geijsen N.
In vitro generation of germ cells from murine embryonic stem cells. Nat Protoc 2006;
1: 2026_36.
16 Nayernia K, Nolte J, Michelmann HW, Lee JH, Rathsack K,
Drusenheimer N, et al. In vitro-differentiated embryonic stem
cells give rise to male gametes that can generate offspring mice.
Dev Cell 2006; 11: 125_32.
17 Nayernia K, Lee JH, Drusenheimer N, Nolte J, Wulf G, Dressel
R, et al. Derivation of male germ cells from bone marrow stem
cells. Lab Invest 2006; 86: 654_63.
18 Drusenheimer N, Wulf G, Nolte J, Lee JH, Dev A, Dressel R,
et al. Putative human male germ cells from bone marrow stem
cells. Soc Reprod Fertil Suppl 2007; 63: 69_76.
19 Lue Y, Erkkila K, Liu PY, Ma K, Wang C, Hikim AS,
et al. Fate of bone marrow stem cells transplanted into the testis:
potential implication for men with testicular failure. Am J Pathol
2007; 170: 899_908.
20 Stashower M, Smith K, Williams J, Skelton H. Stromal
progenitor cells present within liposuction and reduction
abdominoplasty fat for autologous transfer to aged skin.
Dermatol Surg 1999; 25: 945_9.
21 Halvorsen YC, Wilkison WO, Gimble JM. Adipose-derived
stromal cellstheir utility and potential in bone formation.
Int J Obes Relat Metab Disord 2000; 24 (Suppl 4): S41_4.
22 Halvorsen YD, Bond A, Sen A, Franklin DM, Lea-Currie YR,
Sujkowski D, et al. Thiazolidinediones and glucocorticoids
synergistically induce differentiation of human adipose tissue
stromal cells: biochemical, cellular, and molecular analysis.
Metabolism 2001; 50: 407_13.
23 Halvorsen YD, Franklin D, Bond AL, Hitt DC, Auchter C,
Boskey AL, et al. Extracellular matrix mineralization and
osteoblast gene expression by human adipose tissue-derived
stromal cells. Tissue Eng 2001; 7: 729_41.
24 Sen A, Lea-Currie YR, Sujkowska D, Franklin DM, Wilkison
WO, Halvorsen YD, et al. Adipogenic potential of human
adipose derived stromal cells from multiple donors is
heterogeneous. J Cell Biochem 2001; 81: 312_9.
25 Gronthos S, Franklin DM, Leddy HA, Robey PG, Storms
RW, Gimble JM. Surface protein characterization of human
adipose tissue-derived stromal cells. J Cell Physiol 2001; 189:
54_63.
26 Wu P, Sato K, Yukawa S, Hikasa Y, Kagota K. Differentiation
of stromal-vascular cells isolated from canine adipose tissues
in primary culture. J Vet Med Sci 2001; 63: 17_23.
27 Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ,
et al. Multilineage cells from human adipose tissue: implications
for cell-based therapies. Tissue Eng 2001; 7: 211_28.
28 Strem BM, Hicok KC, Zhu M, Wulur I, Alfonso Z, Schreiber
RE, et al. Multipotential differentiation of adipose
tissue-derived stem cells. Keio J Med 2005; 54: 132_41.
29 Valina C, Pinkernell K, Song YH, Bai X, Sadat S, Campeau RJ,
et al. Intracoronary administration of autologous adipose
tissue-derived stem cells improves left ventricular function,
perfusion, and remodelling after acute myocardial infarction.
Eur Heart J 2007; 28: 2667_77.
30 Housman TS, Lawrence N, Mellen BG, George MN, Filippo
JS, Cerveny KA, et al. The safety of liposuction: results of a
national survey. Dermatol Surg 2002; 28: 971_8.
31 Lendeckel S, Jodicke A, Christophis P, Heidinger K, Wolff J,
Fraser JK, et al. Autologous stem cells (adipose) and fibrin
glue used to treat widespread traumatic calvarial defects: case
report. J Craniomaxillofac Surg 2004; 32: 370_3.
32 Moseley TA, Zhu M, Hedrick MH. Adipose-derived stem
and progenitor cells as fillers in plastic and reconstructive
surgery. Plast Reconstr Surg 2006; 118: 121S_8S.
33 Yoshimura K, Sato K, Aoi N, Kurita M, Hirohi T, Harii K.
Cell-assisted lipotransfer for cosmetic breast augmentation:
supportive use of adipose-derived stem/stromal cells.
Aesthetic Plast Surg 2008; 32: 48_55.
34 Fang B, Song YP, Liao LM, Han Q, Zhao RC. Treatment of
severe therapy-resistant acute graft-versus-host disease with
human adipose tissue-derived mesenchymal stem cells. Bone
Marrow Transplant 2006; 38: 389_90.
35 Fang B, Song Y, Lin Q, Zhang Y, Cao Y, Zhao RC,
et al. Human adipose tissue-derived mesenchymal stromal cells as salvage
therapy for treatment of severe refractory acute
graft-vs.-host disease in two children. Pediatr Transplant 2007; 11: 814_7.
36 Fang B, Song Y, Zhao RC, Han Q, Lin Q. Using human
adipose tissue-derived mesenchymal stem cells as salvage therapy
for hepatic graft-versus-host disease resembling acute hepatitis.
Transplant Proc 2007; 39: 1710_3.
37 Ning H, Lin G, Lue TF, Lin CS. Neuron-like differentiation of
adipose tissue-derived stromal cells and vascular smooth
muscle cells. Differentiation 2006; 74: 510_8.
38 Ning H, Lin G, Fandel T, Banie L, Lue TF, Lin CS. Insulin
growth factor signaling mediates neuron-like differentiation of
adipose tissue-derived stem cells. Differentiation 2007. Nov
15 [Epub ahead of publication].
39 Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J,
Frane JL, Tian S, et al. Induced pluripotent stem cell lines
derived from human somatic cells. Science 2007; 318:
1917_20.
40 Nakagawa M, Koyanagi M, Tanabe K, Takahashi K, Ichisaka
T, Aoi T, et al. Generation of induced pluripotent stem cells
without Myc from mouse and human fibroblasts. Nat Biotechnol 2008; 26: 101_6.
41 Hanna J, Wernig M, Markoulaki S, Sun CW, Meissner A,
Cassady JP, et al. Treatment of sickle cell anemia mouse model
with iPS cells generated from autologous skin. Science 2007;
318: 1920_3.
|